on ABIVAX (EPA:ABVX)
Abivax Advances with FDA on Obefazimod for Ulcerative Colitis
Abivax SA, a biotechnology company focused on chronic inflammatory diseases, announced a successful pre-New Drug Application (NDA) interaction with the FDA for its drug candidate obefazimod. This development aligns the company's NDA submission strategy for treating moderate to severe ulcerative colitis in adults.
The company plans to submit its first NDA for obefazimod by the end of 2026. CEO Marc de Garidel highlighted this alignment as a key milestone, following positive Phase 3 ABTECT program results. These results reinforce obefazimod's potential in treating ulcerative colitis.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ABIVAX news